INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene

American Journal of Pathology

Volumn 156, Issue 6, 2000, Pages 1987-1996

  Pinyol, Magda ^a   Hernández, Luis ^a   Martínez, Antonio ^a   Cobo, Francesc ^a   Hernández, Silvia ^a   Beà, Silvia ^a   López Guillermo, Armando ^a   Nayach, Iracema ^a   Palacín, Antonio ^a   Nadal, Alfons ^a   Fernández, Pedro L ^a   Montserrat, Emilio ^a   Cardesa, Antonio ^a   Campo, Elías ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; EXON; GENE INACTIVATION; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0033899352     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65071-7     Document Type: Article

References (45)

1. Genetic alterations in leukemia and lymphomas: Impressive progress and continuing complexity
2. p53 in hematologic malignancies
3. Role of the cyclin-dependent kinase inhibitors in the development of cancer
4. p53, the cellular gatekeeper for growth and division
5. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
6. A novel p16INK4a transcript
7. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
8. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
9. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
10. The INK4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53
11. Functional and physical interactions of the ARF tumor suppressor with p53 and MDM2
12. The alternative product from the human CDKN2a locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
13. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53
14. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of MDM2
15. Role of the INK4a locus in tumor suppression and cell mortality
16. Tumor spectrum in ARF-deficient mice
17. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
18. Inactivations of p16INK4a-alpha, p16INK4a-beta and p15INK4b genes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas
19. Mutations in the CDKN2a (p16INK4a) gene in microdissected sporadic primary melanomas
20. Exclusive p15INK4B gene deletions in acute lymphocytic leukemia include the E1 beta exon of the p16INK4 gene
21. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
22. p16INK4a gene inactivation by deletions, mutations and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
23. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
24. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas
25. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas
26. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants
27. Disregulation of p16MTS1/CDK4l protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx
28. Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors
29. The p16INK4a/CDKN2A tumor suppressor and its relatives
30. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4a/CDKN2, MTS2/ p15INK4b, p53, and Rb genes in primary lymphoid malignancies
31. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies
32. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features
33. Deletions and rearrangement of CDKN2 in lymphoid malignancy
34. Nucleolar ARF sequesters Mdm2 and activates p53
35. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
36. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF
37. Mutational effects on the p16INK4a tumor suppressor protein
38. Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia
39. Review of alterations of the cyclin-dependent kinase inhibitor ink4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
40. The INK4a/ARF locus and its two gene products
41. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
42. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas
43. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16INK4a/MTS1 gene
44. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas
45. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53